Biopharmaceutical company.
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. H.R. 880, the American Research & Competitiveness Act, S. 537. COMPETE Act, and issues related to the R&D tax credit. H.R. 2510 and S. 1660, to make permanent bonus depreciation. Issues related to bonus depreciation. H.R. 1430, to make permanent the CFC look-through rule. S. 1946, the Tax Relief Extension Act of 2015, as it relates to the R&D credit, bonus depreciation, and the CFC look-through rule. Issues related to corporate mergers. H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. The FY'16 budget reconciliation bill as it relates to the repeal of the medical device tax. H.R. 6, The 21st Century Cures Act and the Innovations Initiative. Issues concerning care for chronic disease patients.
TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid BUD - Budget/Appropriations HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
THE NICKLES GROUP, LLC
601 13th St. NW, Suite 250 N, Washington, DC, 20005, US
RACHEL JONES HENSLER MARY BETH SAVARY TAYLOR EMILY PORTER MARY BETH SAVARY TAYLOR EMILY PORTER RACHEL JONES HENSLER MARY BETH SAVARY TAYLOR EMILY PORTER